About JenaValve Technology
JenaValve Technology is a Healthcare company based in Irvine (United States) founded in 2006, and was acquired by Edwards Lifesciences in July 2024. Pericardial transcatheter aortic valve replacement systems are provided. JenaValve Technology has raised $363.7 million across 13 funding rounds from investors including Peijia Medical Technologies, Edwards Lifesciences and Edmond de Rothschild. The company has 198 employees. Its chief executive, as recorded, is John Kilcoyne. JenaValve Technology offers products and services including Trilogy System and ALIGN-AR Study. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its competitors include Shockwave Medical, Cardiac Dimensions and Capstan Medical; 3 of its 3 listed competitors have raised funding.
Company details
Provider of pericardial transcatheter aortic valve replacement and delivery system. It offers Trilogy Valve with locator technology that includes a root valve sewn onto a stent and a delivery system for the treatment of aortic valve stenosis for treatment of patients suffering from the aortic valve insufficiency.
- Headquarters Irvine, United States
- Employees 198
- Stage Acquired
- SectorsHealthcare
- Website jenavalve.com
- Social LinkedIn X
- Acquired by Edwards Lifesciences (Jul 2024)
- Total Equity Funding$363.7M (USD)
in 13 rounds
- Latest Funding Round$100M (USD), Series C
Dec 2021
- InvestorsPeijia Medical Technologies
& 18 more
- Employee Count198
- Acquired byEdwards Lifesciences
(Jul 2024)
Products & Services of JenaValve Technology
JenaValve Technology offers a comprehensive portfolio of products and services, including Trilogy System and ALIGN-AR Study.
Device for treating severe aortic regurgitation in high-risk patients.
Research evaluating safety and efficacy of Trilogy System.
Funding Insights of JenaValve Technology
JenaValve Technology has successfully raised a total of $363.7M across 13 strategic funding rounds. The most recent funding activity was a Series C round of $100 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $363.7M
- Total Rounds 13
- Last Round Series C — $100M
- First Round $4.49M
(Sep 2006)
- Investors Count 18
Latest 10 of 13 funding rounds of JenaValve Technology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2021 | $100M | Series C | – | Bain Capital Life Sciences | |
| Jan 2020 | $66.5M | Series C | – | – | |
| Jun 2019 | $14.49M | Series C | – | – | – |
| Jan 2018 | $14.33M | Debt – Conventional | – | – | – |
| Jul 2017 | $9.39M | Series C | – | – | – |
| Aug 2016 | $10M | Series C | – | – | – |
| Jul 2015 | $26.5M | Series C | – | Valiance Asset Management | |
| Apr 2014 | $10M | Series C | – | Valiance Asset Management, Atlas Venture | |
| Jul 2013 | $73.37M | Series C | – | Gimv, Omega Funds | |
| Mar 2010 | $25.49M | Series B | – | Sunstone, VI Partners |
19 investors in total: 19 institutional.
Investors in JenaValve Technology
JenaValve Technology has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Peijia Medical Technologies, Edwards Lifesciences and Edmond de Rothschild.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | baincapitallifesciences.com | Boston, United States | ||
Capital is provided to firms for growth, buyouts, and acquisitions. | 2001 | anderapartners.com | Paris, France | |
Venture capital fund focused on multiple sectors | valiance-am.com | London, United Kingdom | ||
Private equity firm | 1980 | gimv.com | Antwerp, Belgium | |
Diversified debt funding is provided for growth capital opportunities. | innovatuscp.com | New York, United States | ||
Venture Capital firm focused on multiple sectors | legendcapital.com.cn | Haidian, China | ||
Stage-agnostic life sciences-focused VC firm investing in North America & Europe | neomed.net | Oslo, Norway | ||
Early-stage venture capital is invested in US and Europe. | vipartners.ch | Altendorf, Switzerland | ||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States |
Investor details for JenaValve Technology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of JenaValve Technology
68 people are tracked at JenaValve Technology (23 in leadership, 6 in board & advisors, 39 in team); the tracked headcount is 198.
| Name | Role | Group |
|---|---|---|
John Kilcoyne | CEO | Leadership |
Duane Pinto | Chief Medical Officer | Leadership |
Raghu Aditham | Director Global Quality | Leadership |
Devin Baerenwald | Director, Field Clinical And Training | Leadership |
Jennifer Correa | Sr. Global Director, Regulatory Affairs | Leadership |
Anita Miyake | Director, Program Management | Leadership |
Jane Metcalf | VP, RA and Quality | Leadership |
Kari Moore | Chief Financial Officer | Leadership |
Greg Mirigian | VP, R&D | Leadership |
Jeff Thiel | VP, Operations | Leadership |
Naina Mehta | Director, Clinical Affairs | Leadership |
Angie Gascoigne McIpd | Head Of Hr, UK | Leadership |
Celeste Bonyuet | Sr. Director, Valve Manufacturing Operations | Leadership |
Peter Spadaro | Chief Commercial Officer | Leadership |
Jaden do | Director Global Supply Chain | Leadership |
Connie Correa-Thomson | Human Resources Director | Leadership |
Ryan Polzin | Senior Director - Strategy And Field Operations | Leadership |
Vinod Podichetty (Vinny) | Vice President, Global Clinical & Medical Affairs | Leadership |
Duane Pinto M.D. Mph | Chief Medical Officer | Leadership |
Sean Kim | Senior Director, Clinical Affairs | Leadership |
48 more people are available in the full profile.
Complete people profiles for JenaValve Technology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of JenaValve Technology
4 dated milestones of JenaValve Technology across 18 years, from founding to its latest funding, stage changes and deals.
- Founded JenaValve Technology is founded.
- Funding First funding round of $4.5M.
- Funding Latest funding round, Series C, of $100.0M.
- Exit Acquired by Edwards Lifesciences.
Competitors of JenaValve Technology
JenaValve Technology has 3 listed competitors in our database, 3 of them funded. They include Shockwave Medical, Cardiac Dimensions and Capstan Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| shockwavemedical.com | 2009 | Santa Clara, United States | $147.5M | 1,394 | Cardiovascular balloon dilation catheters with lithotripsy electrodes are developed. | |
| cardiacdimensions.com | 2001 | Kirkland, United States | $260.8M | 31 | Invasive cardiac implants for heart failure treatment are developed. | |
| capstanmedical.com | 2020 | Santa Cruz, United States | $141.4M | Medical devices for structural heart disease treatment are developed. |
Detailed competitors of JenaValve Technology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of JenaValve Technology
The website of JenaValve Technology (jenavalve.com) receives about 5.3K visits a month.
- Monthly visits5.3K
▼ 48.2% vs previous month
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as JenaValve Technology (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Jenavalve Technology
Complete news archive for JenaValve Technology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about JenaValve Technology
JenaValve Technology was founded in 2006.
JenaValve Technology is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
John Kilcoyne is the CEO of JenaValve Technology, as recorded in our data.
JenaValve Technology is a funded company, having raised a total of $363.7M across 13 funding rounds to date. The company's 1st funding round was a Series B of $25.49M, raised on Sep 2006.
JenaValve Technology has 198 employees.
Provider of pericardial transcatheter aortic valve replacement and delivery system. It offers Trilogy Valve with locator technology that includes a root valve sewn onto a stent and a delivery system for the treatment of aortic valve stenosis for treatment of patients suffering from the aortic valve insufficiency.
JenaValve Technology's top competitors include Shockwave Medical, Cardiac Dimensions and Capstan Medical.
JenaValve Technology offers Trilogy System and ALIGN-AR Study.
JenaValve Technology has 19 investors. Key investors include Peijia Medical Technologies, Edwards Lifesciences, Edmond de Rothschild, Gimv, and Andera Partners.
Yes. JenaValve Technology was acquired by Edwards Lifesciences in July 2024.